Show simple item record

dc.contributor.authorHovland, Anders
dc.contributor.authorJonasson, Lena
dc.contributor.authorGarred, Peter
dc.contributor.authorYndestad, Arne
dc.contributor.authorAukrust, Pål
dc.contributor.authorLappegård, Knut Tore
dc.contributor.authorEspevik, Terje
dc.contributor.authorMollnes, Tom Eirik
dc.date.accessioned2016-03-17T11:58:57Z
dc.date.available2016-03-17T11:58:57Z
dc.date.issued2015-06-05
dc.description.abstractDespite recent medical advances, atherosclerosis is a global burden accounting for numerous deaths and hospital admissions. Immune-mediated inflammation is a major component of the atherosclerotic process, but earlier research focus on adaptive immunity has gradually switched towards the role of innate immunity. The complement system and toll-like receptors (TLRs), and the crosstalk between them, may be of particular interest both with respect to pathogenesis and as therapeutic targets in atherosclerosis. Animal studies indicate that inhibition of C3a and C5a reduces atherosclerosis. In humans modified LDL-cholesterol activate complement and TLRs leading to downstream inflammation, and histopathological studies indicate that the innate immune system is present in atherosclerotic lesions. Moreover, clinical studies have demonstrated that both complement and TLRs are upregulated in atherosclerotic diseases, although interventional trials have this far been disappointing. However, based on recent research showing an intimate interplay between complement and TLRs we propose a model in which combined inhibition of both complement and TLRs may represent a potent anti-inflammatory therapeutic approach to reduce atherosclerosisen_US
dc.descriptionPublished version also available at <a href=http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.038>http://dx.doi.org/10.1016/j.atherosclerosis.2015.05.038</a>en_US
dc.identifier.citationAtherosclerosis 2015, 241(2):480-494en_US
dc.identifier.cristinIDFRIDAID 1259338
dc.identifier.doi10.1016/j.atherosclerosis.2015.05.038
dc.identifier.issn0021-9150
dc.identifier.urihttps://hdl.handle.net/10037/9010
dc.identifier.urnURN:NBN:no-uit_munin_8571
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.relation.projectIDNorges forskningsråd: 223255en_US
dc.rights.accessRightsopenAccess
dc.subjectThe complement systemen_US
dc.subjectToll-like receptorsen_US
dc.subjectAtherosclerosisen_US
dc.subjectInflammationen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750en_US
dc.subjectVDP::Medical disciplines: 700::Clinical medical disciplines: 750en_US
dc.titleThe complement system and toll-like receptors as integrated players in the pathophysiology of atherosclerosisen_US
dc.typeJournal articleen_US
dc.typeTidsskriftartikkelen_US
dc.typePeer revieweden_US


File(s) in this item

Thumbnail

This item appears in the following collection(s)

Show simple item record